SLPI Antibody
| Code | Size | Price |
|---|
| PSI-4249-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-4249-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
SLPI Antibody: ALP, MPI, ALK1, BLPI, HUSI, WAP4, WFDC4, HUSI-I, Antileukoproteinase, ALP
Application Note:
SLPI antibody can be used for detection of SLPI by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 10 μg/mL.
Antibody validated: Western Blot in human samples and Immunohistochemistry in mouse samples. All other applications and species not yet tested.
Antibody validated: Western Blot in human samples and Immunohistochemistry in mouse samples. All other applications and species not yet tested.
Background:
SLPI Antibody: Secretory leukocyte protease inhibitor (SLPI) is produced at mucosal surfaces, primarily the upper respiratory tract and is thought to play an important role in the antiprotease defense mechanism of the lung. SLPI forms inhibitory complexes with numerous proteolytic enzymes such as neutrophil elastase, and has been shown to possess anti-inflammatory, anti-viral, and antibacterial activities. Its expression in oral epithelial cells is stimulated by HIV-1 gp120, suggesting that SLPI is a component of the oral mucosal response to HIV-1. In peripheral blood monocytes, SLPI can inhibit NF-κB activation by inhibiting IκB degradation in the cytoplasm and competing for NF-κB binding sites in the nucleus. This attenuation of the inflammatory response may also act to suppress liver metastases and other cancer cell invasions, but promote blood-borne metastasis via an invasion-independent pathway.
Background References:
- Abe T, Kobayashi N, Yoshimura K, et al. Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J. Clin. Invest. 1991; 87:2207-15.
- Hiemstra PS, Fernie-King BA, McMichael J, et al. Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapies. Curr. Pharm. Des. 2004; 10:2891-905.
- Jana NK, Gray LR and Shugars DC. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SPLI) in oral epithelial cells: a role for SLPI in innate mucosal immunity. J. Virol. 2005; 79:6432-40.
- Taggart CC, Cryan S-A, Weldon S, et al. Secretory leucoprotease inhibitor binds to NF-kB binding sites in monocytes and inhibits p65 binding. J. Exp. Med. 2005; 202:1659-68.
Buffer:
SLPI Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Immunogen:
SLPI antibody was raised against a 17 amino acid synthetic peptide from near the center of human SLPI.
The immunogen is located within amino acids 60 - 110 of SLPI.
The immunogen is located within amino acids 60 - 110 of SLPI.
NCBI Gene ID #:
6590
NCBI Official Name:
secretory leukocyte peptidase inhibitor
NCBI Official Symbol:
SLPI
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
Predicted: 15 kDa
Observed: 19 kDa
Observed: 19 kDa
Protein Accession #:
CAA28187
Protein GI Number:
758101
Purification:
SLPI Antibody is affinity chromatography purified via peptide column.
Research Area:
Innate Immunity
Swissprot #:
P03973
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | SLPI Peptide | PSI-4249P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|